Retatrutide + Tesamorelin
otherStacks & Combinations
Research status · Investigational
Combination is not FDA-approved. Retatrutide is investigational and not available by prescription; tesamorelin is FDA-approved only for HIV-associated lipodystrophy.
This combination is discussed at the intersection of GLP/GIP/glucagon research and growth-hormone-axis therapy. It should be understood as an educational overview, not a protocol or recommendation.
How it works
Retatrutide targets incretin and glucagon receptors in obesity and diabetes research. Tesamorelin stimulates endogenous growth hormone release and is approved for a narrow HIV-lipodystrophy indication.
Common components
Commonly discussed purpose
- Body-composition or visceral-fat discussion
- Metabolic and GH-axis discussion
Commonly discussed use cases
- Metabolic research discussion
- Visceral-fat discussion in clinician settings
Supposed / potential benefits
- No approved combined indication
- Any benefit claim for the combination would need controlled clinical evidence
Common side effects
- GI effects from GLP-class agents
- Fluid retention, joint discomfort, IGF-1 and glucose changes from tesamorelin
- Unknown combined tolerability
Warnings & contraindications
- Retatrutide outside a clinical trial is unregulated and not prescription therapy
- Tesamorelin has contraindications and monitoring needs, including IGF-1 and glucose
- Combining metabolic and GH-axis agents requires clinician oversight
Typical timing considerations
No established or recommended combined regimen. Follow approved labels or clinical-trial instructions only where applicable.
Administration route
Subcutaneous injection
Questions to ask your clinician
- Is tesamorelin on-label for me, and is retatrutide only available through a clinical trial?
- What labs and contraindications matter for GH-axis therapy?
- How would we separate side effects from each component?
Commonly tracked in Reta
Tracking fields organize user-entered, clinician-directed routines — Reta never recommends or computes doses.
Track this in Reta
Beta members get a ready-made tracker for Retatrutide + Tesamorelin — schedule, dose log, injection-site rotation, reminders, and check-ins — for organizing a clinician-directed routine. Personal tracking is available to everyone during the Public Beta.
Reta is a tracking and education tool — not a medical provider. Nothing here is a diagnosis, treatment, prescription, or dosing recommendation. Peptides and medications should only be used under the direction of a licensed clinician. Talk to a qualified clinician before starting, stopping, combining, or changing anything. Many compounds below are not FDA-approved for human use; some are investigational or sold through unregulated channels where purity and dosing are not guaranteed.